All Outputs (2)

Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis (2024)
Journal Article
Aldafas, R., Crabtree, T., Alkharaiji, M., Vinogradova, Y., & Idris, I. (2024). Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age and Ageing, 53(1), Article afad254. https://doi.org/10.1093/ageing/afad254

Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) reduce cardio-metabolic and renal outcomes in patients with type 2 diabetes (T2D) but their efficacy and safety in older or frail individuals remains unclear. Methods: We searched PubMed,... Read More about Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.

Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis (2023)
Journal Article
Aldafas, R., Crabtree, T., Vinogradova, Y., Gordon, J. P., & Idris, I. (2023). Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. Expert Review of Endocrinology and Metabolism, 18(1), 95-110. https://doi.org/10.1080/17446651.2023.2166489

Objective: The aim of study is to re-evaluate the risk-benefits of intensive glycemic control in the context of multi-factorial intervention in adults with T2D. Methods: We searched Ovid MEDLINE, Embase, Cochrane, and CINHAL for randomized contro... Read More about Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis.